Jun 23, 2025, 12:40
A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007
NXT007 Hemophilia A Prophylaxis took center stage today when Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X.
“A New Era in Haemophilia A Prophylaxis. Dr. Shima presented groundbreaking phase I/II results for NXT007, a next-generation bispecific antibody: 30 patients with severe haemophilia A (no inhibitors), age range: 12-65 years (median age 39.5 years), subcutaneous dosing: 0.072-1.08 mg/kg every 4 weeks.
Higher dose cohorts (B-3, B-4) achieved FVIII-equivalent activity in the normal range.
Well-tolerated profile with no thromboembolic events, but high anti-drug antibody prevalence: 22/30 patients (73%) and effect on plasma concentrations in 2/22.”
Stay up to date with Hemostasis Today
-
Jul 2, 2026, 11:52Praveen Kumar Tirlangi: A New Mechanism of Bleeding in Kyasanur Forest Disease
-
Jul 2, 2026, 11:17Heghine Khachatryan: Novel Biomarkers for Cancer-Associated Thrombosis
-
Jul 2, 2026, 11:17Neeraj Jain: Maharashtra Is Setting the Pace for Integrated Hemoglobinopathy Care
-
Jul 2, 2026, 11:11Safaa Hilal: Improving Postpartum Hemorrhage Outcomes Through Early Warning Scores
-
Jul 2, 2026, 11:10Maria Khan Junaidi: How Age Influences Intracerebral Hemorrhage Outcomes
-
Jul 2, 2026, 10:51Faces of Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV
-
Jul 2, 2026, 10:29Nisar Ahmed: The Evolution of Anticoagulation Therapy